Scarica l'app Stockscreener
0.94
1.75%
-0.0167
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.9567
Aprire:
$0.9596
Volume 24 ore:
1.36M
Relative Volume:
0.80
Capitalizzazione di mercato:
$177.22M
Reddito:
$154.90M
Utile/perdita netta:
$-20.20M
Rapporto P/E:
-7.8008
EPS:
-0.1205
Flusso di cassa netto:
$-27.91M
1 W Prestazione:
+14.72%
1M Prestazione:
+4.77%
6M Prestazione:
-27.69%
1 anno Prestazione:
-48.91%
Intervallo 1D:
$0.93
$0.9596
Intervallo di 1 settimana:
$0.82
$0.98
Portata 52W:
$0.7362
$2.61
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.94 | 180.37M | 154.90M | -20.20M | -27.91M | -0.1205 |
VRTX
Vertex Pharmaceuticals Inc
|
435.65 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.00 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.13 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
320.70 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
EBITDA per share of Heron Therapeutics Inc – LSE:0J4V - TradingView — Track All Markets
Total debt per share of Heron Therapeutics Inc – LSE:0J4V - TradingView — Track All Markets
Pullback Watch: Can Heron Therapeutics Inc expand into new markets2026 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Heron Therapeutics (HRTX) CEO exercises 62,500 RSUs into common stock - Stock Titan
Earnings Miss: How does Heron Therapeutics Inc compare to its peersQuarterly Trade Summary & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Heron Therapeutics Executive Employment Agreements: Key Terms, Termination, and Restrictive Covenants Explained - Minichart
Heron Therapeutics Strengthens Executive Contracts Amid Strategic Focus - TipRanks
Heron Therapeutics (NASDAQ: HRTX) revises executive severance and CIC - Stock Titan
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Analysts - marketbeat.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of “Hold” by Analysts - Defense World
HRTX Stock Price, Quote & Chart | HERON THERAPEUTICS INC (NASDAQ:HRTX) - ChartMill
Q1 Earnings Forecast for HRTX Issued By Northland Securities - MarketBeat
Moving Averages: How does Heron Therapeutics Inc compare to its peersWeekly Risk Report & Precise Entry and Exit Recommendations - baoquankhu1.vn
Wall Street Recap: How does Heron Therapeutics Inc compare to its peersTrade Entry Summary & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Vanguard realigns holdings; Heron Therapeutics (HRTX) ownership shown as 0 - Stock Titan
What is Northland Securities' Estimate for HRTX Q3 Earnings? - MarketBeat
If You Invested $1,000 in Heron Therapeutics Inc (HRTX) - Stock Titan
Market Trends: Is Heron Therapeutics Inc stock technically oversold2026 Key Highlights & Daily Momentum Trading Reports - baoquankhu1.vn
Clearline Capital LP Increases Holdings in Heron Therapeutics, Inc. $HRTX - MarketBeat
Baker BROS. Advisors LP Purchases New Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
HRTX SEC FilingsHeron Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Citigroup Inc. Increases Stock Position in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Signals Profitable Growth After Strong Quarter - TipRanks
Earnings Call Summary | Heron Therapeutics(HRTX.US) Q4 2025 Earnings Conference - 富途牛牛
HC Wainwright Has Negative Forecast for HRTX FY2026 Earnings - MarketBeat
What is Northland Securities' Forecast for HRTX Q1 Earnings? - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
HRTX Should I Buy - Intellectia AI
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2025 Earnings Call Transcript - Insider Monkey
What is HC Wainwright's Estimate for HRTX Q1 Earnings? - MarketBeat
HRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Heron (HRTX) Q4 2025 Earnings Call Transcript - AOL.com
Heron Therapeutics: Profitable Growth Outlook and Acute Care Momentum Underpin Buy Rating and $3 Target - TipRanks
Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment - MSN
Heron Therapeutics Q4 Earnings Call Highlights - MarketBeat
Heron Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-02-26 - Seeking Alpha
Key facts: Heron Therapeutics projects $173-$183M revenue by 2026; ZYNRELEF adoption rises; credit facilities expanded - TradingView
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Heron Therapeutics, Inc. Provides Earnings Guidance for the Year 2026 - marketscreener.com
Earnings call transcript: Heron Therapeutics Q4 2025 reports strong growth By Investing.com - Investing.com Canada
Heron Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
HRTX: 2025 net revenue rose 7.4% to $154.9M, with strong Acute Care growth and positive EBITDA - TradingView
HERON THERAPEUTICS ($HRTX) Releases Q4 2025 Earnings - Quiver Quantitative
Heron Therapeutics: Q4 Earnings Snapshot - Citizen Tribune
Heron Therapeutics: Fourth Quarter Earnings Overview - Bitget
HERON THERAPEUTICS, INC. /DE/ SEC 10-K Report - TradingView
Heron Therapeutics Q4 revenue dips as Acute Care segment holds fort - TradingView
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.45%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):